Female Reproductive System Carcinoma

subtype

Identifier: CI-CAN-00002685
Entity page: /cancer/female-reproductive-system-carcinoma ↗
Edges: 2,352

Neighbours: 15 genes16 drugs10 trials
Drawn: 41 of 41 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Female Reproductive System Carcinoma approved for …APPROVED_FORderived9 of 9
← approved for	Carboplatinsmall molecule FDA (US) · approved · 2025-08-08 · As part of a combination regimen, for the initial treatment of advanced ovarian carcinoma.	—	approved	Ovarian Carcinoma	1	Regulatory	openfda	graph →
← approved for	Carboplatinsmall molecule

Paths

Strongest chains

Gene → variant → drug chains anchored in this cancer (or a descendant), ranked by source-native evidence level then support, with the approval and trial registry hops when they exist.

BRCA2 Mutation Niraparib6 active / 22 trials
Curatedlevel Asensitivity· support 1civicObservedBRCA2 altered in 3.8% (72 / 1,882 cases, largest of 7 cohorts)no approval record in this cancercontext: Ovarian Carcinoma
BRCA1 Mutation Niraparib6 active / 22 trials
Curatedlevel Asensitivity· support 1civicObservedBRCA1 altered in 1.1% (20 / 1,882 cases, largest of 2 cohorts)no approval record in this cancercontext: Ovarian Carcinoma
BRCA2 Mutation Platinum Compound0 active / 0 trials
Curatedlevel Bsensitivity· support 2civicObservedBRCA2 altered in 3.8% (72 / 1,882 cases, largest of 7 cohorts)no approval record in this cancercontext: Ovarian Carcinoma
BRCA1 Mutation Platinum Compound0 active / 0 trials
Curatedlevel Bsensitivity· support 2civicObservedBRCA1 altered in 1.1% (20 / 1,882 cases, largest of 2 cohorts)no approval record in this cancercontext: Ovarian Carcinoma
ERCC1 Underexpression Platinum Compound0 active / 0 trials
Curatedlevel Bsensitivity· support 1civicObservedcohort frequency not yet available for ERCC1 in this cancerno approval record in this cancercontext: Ovarian Carcinoma
GNAS Mutation Palbociclib5 active / 8 trials
Curatedlevel Bsensitivity· support 1civicObservedcohort frequency not yet available for GNAS in this cancerno approval record in this cancercontext: Pseudomyxoma Peritonei
PIK3CA Amplification Pictilisib0 active / 0 trials
Curatedlevel Csensitivity· support 1civicObservedPIK3CA altered in 44% (824 / 1,882 cases, largest of 20 cohorts)no approval record in this cancercontext: Ovarian Carcinoma
ERBB2 Amplification Trastuzumab3 active / 8 trials
Curatedlevel Csensitivity· support 1civicObservedERBB2 altered in 2.8% (52 / 1,882 cases, largest of 3 cohorts)no approval record in this cancercontext: Endometrial Serous Adenocarcinoma

Each hop keeps its own claim category: cohort alteration frequency (observed, cases ≥ 20), CIViC predictive edge (curated, level as stated by CIViC), regulatory approval (authority, jurisdiction, date as published), trial count (registry). A missing hop is shown as missing — never filled in. Not treatment guidance.

Female Reproductive System Carcinoma altered in cohorts of …ALTERED_INderived15 of 680show all (up to 200)
← altered in cohorts of	MYC 455 / 603 cases (75 %) · ssm · TCGA-OV	—	—	Ovarian Serous Cystadenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	FAM135B 449 / 603 cases (74 %) · ssm · TCGA-OV · largest of 5 cohorts	—	—	Ovarian Serous Cystadenocarcinoma	5	Observed	gdc	graph →
← altered in cohorts of	POU5F1B 449 / 603 cases (74 %) · ssm · TCGA-OV	—	—	Ovarian Serous Cystadenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	ACTRT3 447 / 603 cases (74 %) · ssm · TCGA-OV · largest of 2 cohorts	—	—	Ovarian Serous Cystadenocarcinoma	2	Observed	gdc	graph →
← altered in cohorts of	ADCY8 446 / 603 cases (74 %) · ssm · TCGA-OV	—	—	Ovarian Serous Cystadenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	AGO2 446 / 603 cases (74 %) · ssm · TCGA-OV · largest of 2 cohorts	—	—	Ovarian Serous Cystadenocarcinoma	2	Observed	gdc	graph →
← altered in cohorts of	LRRC34 446 / 603 cases (74 %) · ssm · TCGA-OV · largest of 2 cohorts	—	—	Ovarian Serous Cystadenocarcinoma	2	Observed	gdc	graph →
← altered in cohorts of	MYNN 446 / 603 cases (74 %) · ssm · TCGA-OV · largest of 2 cohorts	—	—	Ovarian Serous Cystadenocarcinoma	2	Observed	gdc	graph →
← altered in cohorts of	PTK2 446 / 603 cases (74 %) · ssm · TCGA-OV	—	—	Ovarian Serous Cystadenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	BCHE 226 / 306 cases (74 %) · ssm · TCGA-CESC	—	—	Cervical Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	CLDN16 226 / 306 cases (74 %) · ssm · TCGA-CESC · largest of 2 cohorts	—	—	Cervical Carcinoma	2	Observed	gdc	graph →
← altered in cohorts of	FNDC3B 226 / 306 cases (74 %) · ssm · TCGA-CESC	—	—	Cervical Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	SPATA16 226 / 306 cases (74 %) · ssm · TCGA-CESC	—	—	Cervical Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	TBL1XR1 226 / 306 cases (74 %) · ssm · TCGA-CESC · largest of 2 cohorts	—	—	Cervical Carcinoma	2	Observed	gdc	graph →
← altered in cohorts of	ZBBX 226 / 306 cases (74 %) · ssm · TCGA-CESC · largest of 2 cohorts	—	—	Cervical Carcinoma	2	Observed	gdc	graph →

Female Reproductive System Carcinoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 182show all (up to 200)
→ investigated in trials for	Paclitaxelsmall molecule 153 trials (47 active) · roll-up of the cancer and its descendants	—	—	Female Reproductive System Carcinoma	153	Observed	clinicaltrials	graph →
→ investigated in trials for	Carboplatinsmall molecule 117 trials (37 active) · roll-up of the cancer and its descendants	—	—	Female Reproductive System Carcinoma	117	Observed	clinicaltrials	graph →
→ investigated in trials for	Bevacizumabmonoclonal antibody 92 trials (34 active) · roll-up of the cancer and its descendants	—	—	Female Reproductive System Carcinoma	92	Observed	clinicaltrials	graph →
→ investigated in trials for	Cisplatinsmall molecule 81 trials (21 active) · roll-up of the cancer and its descendants	—	—	Female Reproductive System Carcinoma	81	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal antibody 61 trials (36 active) · roll-up of the cancer and its descendants	—	—	Female Reproductive System Carcinoma	61	Observed	clinicaltrials	graph →
→ investigated in trials for	Gemcitabinesmall molecule 43 trials (17 active) · roll-up of the cancer and its descendants	—	—	Female Reproductive System Carcinoma	43	Observed	clinicaltrials	graph →
→ investigated in trials for	Cyclophosphamidesmall molecule 36 trials (13 active) · roll-up of the cancer and its descendants	—	—	Female Reproductive System Carcinoma	36	Observed	clinicaltrials	graph →
→ investigated in trials for	Olaparibsmall molecule 36 trials (20 active) · roll-up of the cancer and its descendants	—	—	Female Reproductive System Carcinoma	36	Observed	clinicaltrials	graph →
→ investigated in trials for	Doxorubicinsmall molecule 30 trials (10 active) · roll-up of the cancer and its descendants	—	—	Female Reproductive System Carcinoma	30	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal antibody 30 trials (18 active) · roll-up of the cancer and its descendants	—	—	Female Reproductive System Carcinoma	30	Observed	clinicaltrials	graph →
→ investigated in trials for	Topotecansmall molecule 27 trials (7 active) · roll-up of the cancer and its descendants	—	—	Female Reproductive System Carcinoma	27	Observed	clinicaltrials	graph →
→ investigated in trials for	Fluorouracilsmall molecule 22 trials (4 active) · roll-up of the cancer and its descendants	—	—	Female Reproductive System Carcinoma	22	Observed	clinicaltrials	graph →
→ investigated in trials for	Niraparibsmall molecule 22 trials (6 active) · roll-up of the cancer and its descendants	—	—	Female Reproductive System Carcinoma	22	Observed	clinicaltrials	graph →
→ investigated in trials for	Oxaliplatinsmall molecule 19 trials (4 active) · roll-up of the cancer and its descendants	—	—	Female Reproductive System Carcinoma	19	Observed	clinicaltrials	graph →
→ investigated in trials for	Letrozolesmall molecule 17 trials (8 active) · roll-up of the cancer and its descendants	—	—	Female Reproductive System Carcinoma	17	Observed	clinicaltrials	graph →

Female Reproductive System Carcinoma studied in …STUDIED_INderived10 of 1,481show all (up to 200)
→ studied in	NCT02345265Phase 2 · active not recruiting Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 1,481 trials mapped (543 active)	—	—	Fallopian Tube Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02446600Phase 3 · active not recruiting Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 1,481 trials mapped (543 active)	—	—	Fallopian Tube Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02465060Phase 2 · active not recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) · condition mapped ONTOLOGY_EXACT · 1,481 trials mapped (543 active)	—	—	Cervical Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02502266Phase 2/Phase 3 · active not recruiting Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 1,481 trials mapped (543 active)	—	—	Fallopian Tube Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03348631Phase 2 · active not recruiting Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer · condition mapped CURATED_BROADER · 1,481 trials mapped (543 active)	—	—	Endometrial Endometrioid Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05256225Phase 3 · recruiting Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma · condition mapped ONTOLOGY_EXACT · 1,481 trials mapped (543 active)	—	—	Endometrial Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05564377Phase 2 · recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial · condition mapped CURATED_BROADER · 1,481 trials mapped (543 active)	—	—	Endometrial Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06498661NA · active not recruiting Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S01) · condition mapped ONTOLOGY_EXACT · 1,481 trials mapped (543 active)	—	—	Cervical Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06890338Phase 2 · recruiting A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. · condition mapped ALIAS · 1,481 trials mapped (543 active)	—	—	Ovarian Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07061977Phase 3 · recruiting Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer · condition mapped CURATED_BROADER · 1,481 trials mapped (543 active)	—	—	Cervical Adenocarcinoma	1	Observed	clinicaltrials	graph →